Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...
SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss DrugsSAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Medpage Today on MSN5d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...
(MENAFN- GlobeNewsWire - Nasdaq) Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of health & Human Services, et al. Washington, D.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Today, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback